The most advanced is ISB 1342, a first-generation bispecific antibody targeting both cluster of differentiation 38 (CD38) on myeloma cells and CD3 on T cells, which is in phase 1 testing for ...

Based on the team's discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

A recent Phase II trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce ...

The French pharma group has filed anti-CD38 antibody Sarclisa (isatuximab) for use in combination with Takeda’s Velcade (bortezomib), lenalidomide, and dexamethasone – known as the VRd regimen ...

A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients' kidney function. Investigators evaluated the ...

The label expansion for the anti-CD38 antibody was supported by data from the ongoing Phase III PERSEUS trial that was submitted to to the European Medicines Agency in March 2024. Darzalex ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...